- Home
- OESX vs SABS Comparison
OESX vs SABS Comparison
Compare OESX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OESX
- SABS
- Stock Information
- Founded
- OESX 1996
- SABS 2014
- Country
- OESX United States
- SABS United States
- Employees
- OESX N/A
- SABS N/A
- Industry
- OESX Building Products
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- OESX Consumer Discretionary
- SABS Health Care
- Exchange
- OESX Nasdaq
- SABS Nasdaq
- Market Cap
- OESX 27.5M
- SABS 23.9M
- IPO Year
- OESX 2007
- SABS N/A
- Fundamental
- Price
- OESX $0.82
- SABS $3.13
- Analyst Decision
- OESX Strong Buy
- SABS Strong Buy
- Analyst Count
- OESX 1
- SABS 5
- Target Price
- OESX $3.00
- SABS $12.40
- AVG Volume (30 Days)
- OESX 72.0K
- SABS 83.6K
- Earning Date
- OESX 11-06-2024
- SABS 11-06-2024
- Dividend Yield
- OESX N/A
- SABS N/A
- EPS Growth
- OESX N/A
- SABS N/A
- EPS
- OESX N/A
- SABS N/A
- Revenue
- OESX $91,649,000.00
- SABS $1,512,723.00
- Revenue This Year
- OESX $13.74
- SABS N/A
- Revenue Next Year
- OESX $14.83
- SABS N/A
- P/E Ratio
- OESX N/A
- SABS N/A
- Revenue Growth
- OESX 14.40
- SABS N/A
- 52 Week Low
- OESX $0.81
- SABS $2.16
- 52 Week High
- OESX $1.53
- SABS $9.72
- Technical
- Relative Strength Index (RSI)
- OESX 33.60
- SABS 48.83
- Support Level
- OESX $0.92
- SABS $2.95
- Resistance Level
- OESX $0.94
- SABS $3.74
- Average True Range (ATR)
- OESX 0.05
- SABS 0.43
- MACD
- OESX -0.02
- SABS -0.07
- Stochastic Oscillator
- OESX 0.10
- SABS 13.14
About OESX Orion Energy Systems Inc.
Orion Energy Systems Inc is a developer, manufacturer, and seller of lighting and energy management systems. The company segments include Orion Lighting Segment, Orion Maintenance Segment and Orion Electric Vehicle Charging Segment. It derives maximum revenue from Lighting Segment.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.